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We evaluated the risk of angiosarcoma after radiotherapy among all patients with cancers of breast, cervix uteri, corpus uteri, lung,
ovary, prostate, or rectum, and lymphoma diagnosed in Finland during 1953–2003, identified from the Finnish Cancer Registry. Only
angiosarcomas of the trunk were considered, this being the target of radiotherapy for the first cancer. In the follow-up of 1.8 million
person-years at risk, 19 angiosarcomas developed, all after breast and gynaecological cancer. Excess of angiosarcomas over national
incidence rates were observed after radiotherapy without chemotherapy (standardised incidence ratio (SIR) 6.0, 95% confidence
interval (CI) 2.7–11), after both radiotherapy and chemotherapy (SIR 100, 95% CI 12–360), and after other treatments (SIR 3.6, 95%
CI 1.6–7.1). In the regression analysis however, the adjusted rate ratio for radiotherapy was 1.0 (95% CI 0.23–4.4). Although an
increased risk of angiosarcoma among cancer patients is evident, especially with breast and gynaecological cancer, the excess does
not appear to be strongly related to radiotherapy.
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Sarcomas are malignant mesenchymal tumours and angiosarcoma
develops from the endothelium of a blood vessel. It is an
uncommon cancer type that occurs among men and women, more
often among older adults and usually in the skin, soft tissue,
breast, or liver (Schoen and Cotran, 1999).
The risk of a second cancer is increased among persons who
have had a cancer previously (IARC, 2000), owing both to shared
risk factors and treatment for the first cancer, both chemotherapy
and radiotherapy increasing cancer risk. In our previous study,
radiotherapy was found to be a risk factor for subsequent bone and
soft tissue sarcoma (Virtanen et al, 2006). Ionising radiation is one
of the few known causes of angiosarcoma (Miller et al, 1996; Zahm
et al, 1996; Huang and Mackillop, 2001; Fletcher et al, 2002; Yap
et al, 2002). We have investigated the risk of angiosarcoma in
relation to chemotherapy and radiotherapy in a large, population-
based cohort of cancer patients.
MATERIALS AND METHODS
The study cohort included patients with first primary cancers
diagnosed during 1953–2003 in the Finnish Cancer Registry
database, which has almost complete coverage of cancers in
Finland since 1953 (Teppo et al, 1994). National Research and
Development Centre for Welfare and Health (STAKES) granted the
permission to use the Finnish Cancer Registry database.
The cohort included patients with first primary cancers of the
breast, cervix uteri, corpus uteri, lung, ovary, prostate, and rectum,
as well as Hodgkin’s and non-Hodgkin’s lymphomas, selected
because they are treated both with radiotherapy and other
modalities, mainly chemotherapy, surgery, and hormonal therapy.
Small-cell carcinoma of the lung was excluded because it is rarely
treated with radiation therapy. In addition, radiotherapy for these
cancers involves almost exclusively the trunk, which allowed
restriction of the end point and hence more specific evaluation
of the effect, by exclusion of angiosarcomas in the head and
extremities, that is, outside the radiation beam. The selected
cancers are relatively common and constitute 47% of all the
registered cancers in men and 50% in women in 1953–2003 in
Finland (Finnish Cancer Registry, 2005).
The analyses were stratified by type, treatment, cancer site, and
age at diagnosis (10-year age group) of the first cancer, sex, and
length of follow-up time (0, 1–4, 5–9, 10–14, 15, or more years
since diagnosis of the first primary cancer). Treatment was
classified into four groups: treatment without chemotherapy or
radiotherapy (e.g. surgery or hormonal treatment), chemotherapy
without radiotherapy, radiotherapy without chemotherapy, and
combined chemotherapy and radiotherapy.
The cohort was followed up for subsequent angiosarcomas and
lymphangiosarcomas, starting at diagnosis of the first primary
cancer and ending at death, emigration, diagnosis of angio-
sarcoma, or the common closing date (31 December 2003).
Information on emigration and vital status was obtained
from the Population Register Centre by computerised record
linkage.
The outcome event was defined as a histologically confirmed
angiosarcoma or lymphangiosarcoma on the trunk, those outside
the trunk being excluded, as only radiation treatment to the trunk
is relevant to the study. The anatomic sites of the first cancer
included oesophagus, stomach, small intestine, large intestine,
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yrectum, biliary ducts, gallbladder, liver, pancreas, lung, media-
stinum, breast, cervix uteri, corpus uteri, uterus and other female
reproductive organs, ovary, prostate, kidney, bladder, urinary tract,
skin of the trunk, bone of the trunk, and soft tissue of the trunk.
Expected numbers were calculated by multiplying the person-
years at risk with the national incidence rates stratified by sex, 5-
year calendar period, and 5-year age group. The standardised
incidence ratio (SIR) was calculated as the ratio of observed to
expected numbers of cases. The 95% confidence intervals (CI) were
estimated assuming that the observed number followed Poisson
distribution and the expected number being constant (Breslow and
Day, 1989). As the estimated minimal latency time for radiation-
induced solid tumours is 10 years (Boice et al, 1996), special focus
was given to the follow-up time of 10 or more years after diagnosis
of the first primary cancer. To adjust for the effects of age, sex,
follow-up time, and first primary cancer type, which may differ
between treatment categories, Poisson regression modelling was
used (Clayton and Hills, 1993). Cumulative incidence (Satagopan
et al, 2004) was assessed as an estimate of angiosarcoma risk at 10
years of follow-up. Also, the number needed to harm (Walter,
2000) was evaluated as an estimate of the number of patients who
should receive radiotherapy in order to induce one excess sarcoma
during 10 years of follow-up. The Stata 8.0 software (Stata
Corporation, College Station, TX, USA) was used in the analysis.
RESULTS
The cohort included a total of 332163 patients with first primary
cancers. Among the cohort members, 54% were women and 76%
were aged 55 years or more at the time of diagnosis of the first
primary cancer. Mean age was 59 years among patients with
radiotherapy and 66 years among patients without radiotherapy.
The follow-up yielded 1.79 million person-years at risk, with a
mean length of follow-up time of 5.4 years. Of the total person-
time at risk, 4% was provided by the patients receiving both
radiotherapy and chemotherapy, 41% after radiotherapy alone,
and 5% after chemotherapy alone.
In the follow-up, 19 cases of angiosarcoma were observed vs 3.8
expected (Table 1), all in women; 12 of the cases were in patients
over 55 years at diagnosis of the first cancer. No lymphangiosarco-
mas were recorded in the follow-up. At 10 years of follow-up, the
cumulative incidence, directly standardised by age, for angio-
sarcoma was 0.02/1000 (95% CI 0.00/1000–0.06/1000) for patients
who were not treated with radiotherapy. After radiotherapy with or
without chemotherapy, cumulative incidence was 0.06/1000 (95% CI
0.02/1000–0.11/1000), that is, one excess case expected within 10
years among 22200 patients receiving radiation treatment.
Overall, the risk of angiosarcoma was increased in every
treatment group, except after chemotherapy alone, among whom
no angiosarcomas were found (Table 1). In the radiotherapy
group, nine cases were found, SIR 6.0 (95% CI 2.7–11) for the
entire follow-up and SIR 4.1 (95% CI 0.84–12) for the follow-up of
10 or more years. Risk was higher for patients treated with both
radiotherapy and chemotherapy, SIR 100 (95% CI 2.5–560, two
cases) for the follow-up after 10 years, when it was also increased
among patients not treated with radiotherapy or chemotherapy.
Among women after radiotherapy with or without chemotherapy,
risk was increased (SIR 5.3, 95% CI 1.5–14, four cases) for follow-
up of 10 years or more (Table 2). After 10 years of follow-up, an
excess risk was also found among patients not treated with
radiotherapy, SIR 7.7 (95% 2.1–20, four cases). No consistent
pattern of risk in relation to age at observation was observed.
The angiosarcomas occurred among patients with cancers of the
breast, cervix uteri, corpus uteri, and ovary, the majority of them
(14 observed cases vs 1.7 expected) being among breast cancer
patients (Table 2). Among the latter treated with radiotherapy with
or without chemotherapy, a significant excess risk was found, SIR
11 (95% CI 4.8–20) for the entire follow-up time.
In the regression analysis, the crude rate ratio was 0.94 (95% CI
0.34–2.6) for the radiotherapy group, compared to those not so
treated, and was not materially affected by adjustment for age, first
cancer type, and follow-up time (RR 1.0 95% CI 0.23–4.4). A
separate regression analysis for breast cancer patients gave an
adjusted RR of 1.0 (95% CI 0.23–4.4) for radiotherapy. The effect
of treatment did not differ significantly by age, follow-up time, or
site of the first cancer type (P40.1).
Table 2 Observed and expected numbers of angiosarcomas and SIR for breast and other cancers by follow-up time, and radiation treatment for the first
primary cancer 1953–2003
Entire follow-up Follow-up of 10 or more years
First primary cancer Radiotherapy O/E SIR (95% CI) O/E SIR (95% CI)
Breast Yes 9/0.85 11 (4.8–20) 2/0.36 5.6 (0.67–20)
No 5/0.84 6.0 (1.9–14) 1/0.28 3.6 (0.09–20)
Total 14/1.7 8.3 (4.5–14) 3/0.64 4.7 (1.0–14)
Other
a Yes 2 /0.61 3.3 (0.40–12) 2/0.39 5.1 (0.62–18)
No 3/0.56 5.4 (1.1–16) 3/0.24 13 (2.6–37)
Total 5/1.2 4.3 (1.4–9.9) 5/0.63 7.9 (2.6–18)
Total Yes 11/1.5 7.5 (3.8–13) 4/0.75 5.3 (1.5–14)
No 8/1.4 5.7 (2.4–11) 4/0.52 7.7 (2.1–20)
Total 19/2.9 6.6 (4.0–10) 8/1.3 6.3 (2.7–12)
CI¼confidence interval; E¼expected; O¼observed; SIR¼standardised incidence ratios.
aAfter cancers of cervix uteri (one case with and one without radiotherapy), corpus
uteri (two without radiotherapy), and ovary (one with radiotherapy).
Table 1 Observed and expected numbers of angiosarcomas on the
trunk and SIR by follow-up time and treatment for the first primary cancer
1953–2003
Entire follow-up
Follow-up of 10
or more years
Treatment O/E SIR (95% CI) O/E SIR (95% CI)
Chemotherapy 0/0.07 0.0 (0–53) 0/0.02 0.0 (0–180)
Radiotherapy 9/1.5 6.0 (2.7–11) 3/0.74 4.1 (0.84–12)
Both 2/0.02 100 (12–360) 1/0.01 100 (2.5–560)
Neither 8/2.2 3.6 (1.6–7.1) 4/0.61 6.6 (1.8–17)
Total 19/3.8 5.0 (3.0–7.8) 8/1.4 5.8 (2.5–11)
CI¼confidence interval; E¼expected; O¼observed; SIR¼standardised incidence
ratios.
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Our results indicate that our cancer patients have a five-fold
elevated risk of angiosarcoma compared with the rest of the
population. All cases were in women and were confined to patients
with breast or gynaecological cancers. We did not find a strong
relationship with radiotherapy, but our findings are consistent
with an increased risk related to combined radiotherapy and
chemotherapy. However, despite the large cohort with more than
330000 patients with first primary cancer, the number of
angiosarcomas was small.
The results of this study are consistent with the few previous
studies of angiosarcoma after radiotherapy. In a SEER data study
of second malignancies among 270000 breast cancer patients,
angiosarcomas were found to comprise 56.8% of the sarcomas
occurring in the field of prior radiation (Yap et al, 2002). In a
population-based retrospective cohort study of 195000 breast
carcinoma patients, an increased risk of soft tissue sarcoma was
found, especially for angiosarcoma: SIR 26.2 (95% CI 16.5–41.4) in
the radiotherapy cohort with an increased relative risk (RR 15.9,
95% CI 6.6–38.1) compared to those not so treated (Huang and
Mackillop, 2001); the SIRs were lower in our study, with no excess
after radiotherapy compared with other treatments.
Post-irradiation sarcomas have mainly followed breast and
gynaecologic cancers (Kim et al, 1998), breast cancer, lymphoma,
and carcinoma of cervix (Brady et al, 1992), and cancers of breast
and female reproductive organs (Wiklund et al, 1991). In our study,
the angiosarcoma cases occurred following breast cancer and
gynaecologic cancers, with no cases among men. This suggests an
association between female hormonal factors and angiosarcoma.
In previous studies, the minimal latency for radiation to cause a
solid tumour has been estimated as 10 years (IARC, 2000). In a
cohort study of breast cancer patients, the RR of angiosarcoma
after radiotherapy reached its maximum during 5–10 years of
follow-up (Huang and Mackillop, 2001). Our study indicates an
increased angiosarcoma risk after 10 years both after radiotherapy
and other treatments. The cumulative incidence at 10 years
indicated an increased risk related to radiotherapy, not observed in
other analyses, owing to an early excess (within 10 years of
treatment).
Patient or disease characteristics other than treatment may
confound the results, if they affect angiosarcoma risk. Several
factors influence selection for radiotherapy (Easson, 1991).
Features such as detailed treatment scheme, tumour location, or
histology were not evaluated in this study and further case–
control analyses are needed.
We were unable to determine whether the angiosarcoma of the
trunk occurred within the irradiated volume, or to provide
measures of risk related to doses to specific organs, but only
estimates of the overall risk of angiosarcoma.
By basing our study on comparisons of patients with similar
first cancers and different forms of treatment, the effect of
aetiologic factors underlying the first cancer were largely
eliminated as a possible cause of the angiosarcoma. Another
strength of this study was the large, representative study
population, covering practically all eligible Finnish cancer patients
diagnosed during 1953–2003, while record-linkage with the
population registry allowed complete follow-up.
These results indicate an increased risk of angiosarcoma among
cancer patients, especially those with breast and gynaecological
cancers. Similar increased risks were found both among patients
treated with radiotherapy and those without radiotherapy. Further
analyses focusing more closely on the irradiated tissue and dose–
response are needed.
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